A 2-Month Safety Follow-up Trial of Subjects From MannKind Protocols MKC-TI-009, MKC-TI-102, MKC-TI-103 and MKC-TI-030.
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2014
At a glance
- Drugs Insulin (Primary) ; Antihyperglycaemics
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors MannKind Corporation
- 24 Apr 2010 Results were presented at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster 267), according to a MannKind Corporation media release.
- 23 May 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 22 May 2009 Actual patient number (672) added as reported by ClinicalTrials.gov.